4//SEC Filing
Sagent Pharmaceuticals, Inc. 4
Accession 0000899243-16-028315
CIK 0001369786operating
Filed
Aug 30, 8:00 PM ET
Accepted
Aug 31, 6:25 PM ET
Size
19.1 KB
Accession
0000899243-16-028315
Insider Transaction Report
Form 4
Jonathon M Singer
Chief Financial Officer
Transactions
- Disposition from Tender
Common Stock
2016-08-29$21.75/sh−7,857$170,890→ 27,206 total - Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−27,206$591,731→ 0 total - Disposition to Issuer
Common Stock
2016-08-29$21.75/sh−3,665$79,714→ 35,063 total - Disposition to Issuer
Stock Option to Buy
2016-08-29$7.14/sh−34,783$248,351→ 0 totalExercise: $14.61Exp: 2026-02-22→ Common Stock (34,783 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$1.59/sh−10,638$16,914→ 0 totalExercise: $20.16Exp: 2024-02-18→ Common Stock (10,638 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$1.65/sh−55,000$90,750→ 0 totalExercise: $20.10Exp: 2021-09-19→ Common Stock (55,000 underlying) - Disposition to Issuer
Stock Option to Buy
2016-08-29$5.30/sh−12,067$63,955→ 0 totalExercise: $16.45Exp: 2023-02-21→ Common Stock (12,067 underlying)
Footnotes (7)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were canceled and converted into the right to receive $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Consideration").
- [F2]Pursuant to the Merger Agreement, these shares were disposed of in a cash tender offer by Shepard Vision, Inc. to acquire common stock of Sagent Pharmaceuticals, Inc. in exchange for the Consideration.
- [F3]Pursuant to the Merger Agreement, these restricted shares were canceled and converted into the right to receive the Consideration.
- [F4]Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F5]Represents the disposition of options, which provided for vesting in four equal installments beginning February 18, 2015. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.59 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F6]Represents the disposition of options, which provided for vesting in four equal installments beginning February 21, 2014. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $5.30 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
- [F7]Represents the disposition of options, which provided for vesting in four equal installments beginning September 19, 2012. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.65 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
Documents
Issuer
Sagent Pharmaceuticals, Inc.
CIK 0001369786
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001369786
Filing Metadata
- Form type
- 4
- Filed
- Aug 30, 8:00 PM ET
- Accepted
- Aug 31, 6:25 PM ET
- Size
- 19.1 KB